Mp15-13 Characterization of the Immune Infiltration in High Grade Nmibc: Immunvessie Project

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I (MP15)1 May 2024MP15-13 CHARACTERIZATION OF THE IMMUNE INFILTRATION IN HIGH GRADE NMIBC: IMMUNVESSIE PROJECT Clément Klein, Thomas Boyer, Aurélia Le Dantec, Samy Mebroukine, Grégoire Robert, Nicolas Larmonier, and Charlotte Domblides Clément KleinClément Klein , Thomas BoyerThomas Boyer , Aurélia Le DantecAurélia Le Dantec , Samy MebroukineSamy Mebroukine , Grégoire RobertGrégoire Robert , Nicolas LarmonierNicolas Larmonier , and Charlotte DomblidesCharlotte Domblides View All Author Informationhttps://doi.org/10.1097/01.JU.0001009500.87761.bf.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Despite resection followed by BCG instillations, the prognosis of high-risk NMIBC remains poor due to frequent recurrences. In our study, we aimed at evaluating the expression of PD-L1 (as immunotherapies targeting PD-1/PD-L1 has shown promising results in the metastatic setting) and at characterizing the immune context of high-grade pTa and Cis to better understand the role of BCG in relapsing NMIBC. METHODS: We selected 100 FFPE tumors from patients treated for NMIBC at the CHU Bordeaux, with corresponding clinical data. The CPS PD-L1 score (Combined Positive Score) was assessed by an expert pathologist, and transcriptomic analysis were performed using NanoString technology before and after BCG exposure. RESULTS: Only 51 tumors were assessable due to low-quality tissue after pathological review. The patient characteristics are presented in Table 1. Regarding the relapse-free survival rate, we did not find any significant difference with respect to CPS status (p=0.7). In contrast, the OS rate was significantly higher in the CPS-neg group (p=0.003) (Figure 1). Furthermore, we found gene signatures evoking higher tumor cell intrinsic resistance, and an impaired effector phase through decreased T cell activation and/or higher potent myeloid immunosuppressive infiltrate (Figure 2) in relapsing NMIBC. CONCLUSIONS: Our current study provides some hints that targeting PD-1/PD-L1 axis and/or the myeloid immunosuppressive environment may represent an interesting alternative to BCG-therapy, to improve patient prognosis. Download PPTDownload PPT Source of Funding: Astra Zeneca © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e234 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Clément Klein More articles by this author Thomas Boyer More articles by this author Aurélia Le Dantec More articles by this author Samy Mebroukine More articles by this author Grégoire Robert More articles by this author Nicolas Larmonier More articles by this author Charlotte Domblides More articles by this author Expand All Advertisement PDF downloadLoading ...